Acute Effects of Heated Tobacco Product (IQOS) Aerosol Inhalation on Lung Tissue Damage and Inflammatory Changes in the Lungs
Overview
Authors
Affiliations
Introduction: Emerging heated tobacco products (HTPs) were designed to reduce exposure to toxicants from cigarette smoke (CS) by avoiding burning tobacco and instead heating tobacco. We studied the effects of short-term inhalation of aerosols emitted from HTP called IQOS, on lung damage and immune-cell recruitment to the lungs in mice.
Methods: Numerous markers of lung damage and inflammation including albumin and lung immune-cell infiltrates, proinflammatory cytokines, and chemokines were quantified in lungs and bronchoalveolar (BAL) fluid from IQOS, CS, or air-exposed (negative control) mice.
Results: Importantly, as a surrogate marker of lung epithelial-cell damage, we detected significantly increased levels of albumin in the BAL fluid of both HTP- and CS-exposed mice compared with negative controls. Total numbers of leukocytes infiltrating the lungs were equivalent following both IQOS aerosols and CS inhalation and significantly increased compared with air-exposed controls. We also observed significantly increased numbers of CD4+IL-17A+ T cells, a marker of a T-cell immune response, in both groups compared with air controls; however, numbers were the highest following CS exposure. Finally, the numbers of CD4+RORγt+ T cells, an inflammatory T-cell subtype expressing the transcription factor that is essential for promoting differentiation into proinflammatory Th17 cells, were significantly augmented in both groups compared with air-exposed controls. Levels of several cytokines in BAL were significantly elevated, reflecting a proinflammatory milieu.
Conclusions: Our study demonstrates that short-term inhalation of aerosols from IQOS generates damage and proinflammatory changes in the lung that are substantially similar to that elicited by CS exposure.
Implications: Exposure of mice to IQOS, one of the candidate modified-risk tobacco products, induces inflammatory immune-cell accumulation in the lungs and augments the levels of proinflammatory cytokines and chemokines in the BAL fluid. Such an exacerbated pulmonary proinflammatory microenvironment is associated with lung epithelial-cell damage in IQOS-exposed mice, suggesting a potential association with the impairment of lung function.
Kim B, Yang W, Seong Y, Choi Y, Park H, Byun M Int J Mol Sci. 2025; 26(3).
PMID: 39940903 PMC: 11817633. DOI: 10.3390/ijms26031135.
Bhat T, Kalathil S, Leigh N, Goniewicz M, Thanavala Y Respir Res. 2024; 25(1):381.
PMID: 39427167 PMC: 11491011. DOI: 10.1186/s12931-024-02992-y.
Mercincavage M, Wackowski O, Chen-Sankey J, Thrasher J, Audrain-McGovern J, Strasser A Nicotine Tob Res. 2024; 27(2):351-359.
PMID: 39109909 PMC: 11750736. DOI: 10.1093/ntr/ntae195.
Challenges in current inhalable tobacco toxicity assessment models: A narrative review.
Muthumalage T, Noel A, Thanavala Y, Alcheva A, Rahman I Tob Induc Dis. 2024; 22.
PMID: 38860150 PMC: 11163881. DOI: 10.18332/tid/188197.
A scoping review of the toxicity and health impact of IQOS.
Ghazi S, Song M, El-Hellani A Tob Induc Dis. 2024; 22.
PMID: 38832049 PMC: 11145630. DOI: 10.18332/tid/188867.